Related Experiment Video
Updated: Mar 1, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary
Garry R Barton1, Lisa Irvine1, Marcus Flather1
1Norwich Medical School, University of East Anglia, Norwich, UK.
Insights
Complete revascularization during ST-segment elevation myocardial infarction is more effective and cost-effective than treating only the infarct-related artery. This approach reduces major adverse cardiac events and hospital costs, offering better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Interventional Cardiology
Background:
- ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease often require percutaneous coronary intervention (P-PCI).
- The optimal revascularization strategy, complete versus infarct-related artery (IRA) only, remains an area of economic and clinical evaluation.
Purpose of the Study:
- To determine the cost-effectiveness of complete revascularization versus IRA-only P-PCI in STEMI patients with multivessel disease.
- To compare major adverse cardiac events (MACEs) and quality-adjusted life-years (QALYs) between the two strategies.
Main Methods:
- Economic evaluation of a multicenter randomized trial with 12-month follow-up.
- Estimation of overall hospital costs, including P-PCI procedures, hospital stay, and re-admissions.
- Assessment of MACEs and QALYs using the EuroQol five-dimensional questionnaire.
Main Results:
- Complete revascularization was associated with a mean cost reduction of -£215.96 and a reduction of 0.170 MACEs per patient.
- A gain of 0.011 QALYs was observed with complete revascularization.
- The probability of complete revascularization being cost-effective was 72.0% at a willingness-to-pay threshold of £20,000 per QALY.
Conclusions:
- Complete revascularization at index admission is more effective and cost-effective for STEMI patients with multivessel disease.
- This strategy dominates IRA-only treatment, showing lower costs and improved clinical outcomes.
- While the results suggest a clear benefit, some uncertainty remains in the decision-making process.
Objectives:
To determine the cost-effectiveness of complete revascularization at index admission compared with infarct-related artery (IRA) treatment only, in patients with multivessel disease undergoing primary percutaneous coronary intervention (P-PCI) for ST-segment elevation myocardial infarction.
Methods:
An economic evaluation of a multicenter randomized trial was conducted, comparing complete revascularization at index admission to IRA-only P-PCI in patients with multivessel disease (12-month follow-up). Overall hospital costs (costs for P-PCI procedure(s), hospital length of stay, and any subsequent re-admissions) were estimated. Outcomes were major adverse cardiac events (MACEs, a composite of all-cause death, recurrent myocardial infarction, heart failure, and ischemia-driven revascularization) and quality-adjusted life-years (QALYs) derived from the three-level EuroQol five-dimensional questionnaire. Multiple imputation was undertaken. The mean incremental cost and effect, with associated 95% confidence intervals, the incremental cost-effectiveness ratio, and the cost-effectiveness acceptability curve were estimated.
Results:
On the basis of 296 patients, the mean incremental overall hospital cost for complete revascularization was estimated to be -£215.96 (-£1390.20 to £958.29), compared with IRA-only, with a per-patient mean reduction in MACEs of 0.170 (0.044 to 0.296) and a QALY gain of 0.011 (-0.019 to 0.041). According to the cost-effectiveness acceptability curve, the probability of complete revascularization being cost-effective was estimated to be 72.0% at a willingness-to-pay threshold value of £20,000 per QALY.
Conclusions:
Complete revascularization at index admission was estimated to be more effective (in terms of MACEs and QALYs) and cost-effective (overall costs were estimated to be lower and complete revascularization thereby dominated IRA-only). There was, however, some uncertainty associated with this decision.
More Related Videos
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies

